Revised ALS Clinical Trials Consensus Guidelines Modernize Trial Practices

The ALS Association is proud to be a longtime supporter of the Airlie House ALS Clinical Trials Consensus Guidelines, which have been revised and published in Neurology, the most widely read and highly cited peer-reviewed neurology journal.

The goal of the Guidelines is to improve research to test cures for ALS. We believe they will pave the way to decrease clinical trial burden for people with ALS and help contribute innovative designs to clinical trials.

Continue reading Revised ALS Clinical Trials Consensus Guidelines Modernize Trial Practices

Biogen to Present Promising Results of Phase 1/2 Trial of Antisense Targeting SOD1

Next week at the American Academy of Neurology Meeting (AAN) in Philadelphia, Biogen will present promising results of the phase 1/2 study of its newly named investigational therapy tofersen (previously BIIB067), which is now enrolling in a phase 3 trial. Tofersen is an antisense oligonucleotide (ASO), a type of designer DNA drug, targeting SOD1.

The ALS Association is proud to be the first funder of antisense technology.  Our support   dates back to 2004, when antisense was just an idea in Dr. Don Cleveland’s lab at University of California San Diego (UCSD). This new potential treatment targets the second most common cause of inherited ALS, mutations in the SOD1 gene.

Continue reading Biogen to Present Promising Results of Phase 1/2 Trial of Antisense Targeting SOD1

Meet Andrei Ursu: A 2018 Milton Safenowitz Postdoctoral Fellow

Our Milton Safenowitz Postdoctoral Fellowship Program continues to support young scientists and is the only program of its kind specifically funding early ALS postdoctoral fellows.

The awards were founded in memory of Mr. Safenowitz by the Safenowitz family – through The ALS Association Greater New York Chapter. The program encourages young scientists to enter and, importantly, to remain in the ALS field.

We are proud that 76 percent of the postdoctoral fellows we fund go on to start their own labs to continue studying ALS and mentor other young ALS researchers. The rest of our Safenowitz fellowship program graduates go on to careers in the biomedical industry, nonprofits, and medical writing, with many still staying in the ALS space.

This year, we are supporting five new postdoctoral fellows out of a highly competitive applicant pool. Over the next few weeks, we will highlight each fellow – their dedication and unique contributions to ALS research, as well as their interests outside of the lab.

We recently talked with Dr. Andrei Ursu from The Scripps Research Institute (Florida Campus) to learn about his unique research project focused on targeting the most common form of genetically inherited ALS, known as c9ALS, with rationally designed lead medicines.

Continue reading Meet Andrei Ursu: A 2018 Milton Safenowitz Postdoctoral Fellow

A Look Back at Over $16 Million in Research Grants Awarded During 2018

Investments are Accelerating Innovation and Progress Toward a Cure

It’s ALS Awareness Month, and The ALS Association remains steadfastly committed to funding the most hopeful research around the world that could lead to effective treatments and a cure for ALS.

Since the ALS Ice Bucket Challenge soaked the world almost five years ago, we have tripled our annual research budget.

More than $108 million has been committed toward our mission, including over $89 million that has been committed to worldwide research collaborations, since 2014. In 2018 alone, we awarded more than $16 million ($16,079,742) in funding to support 47 new research projects in nine countries*.

To see a complete list of the research we have funded since the ALS Ice Bucket Challenge, click here. For a list of all the grants we fund, click here.

Continue reading A Look Back at Over $16 Million in Research Grants Awarded During 2018

Meet Alyssa Coyne: A 2018 Milton Safenowitz Postdoctoral Fellow

Our Milton Safenowitz Postdoctoral Fellowship Program continues to support young scientists and is the only program of its kind specifically funding early ALS postdoctoral fellows.

The awards were founded in memory of Mr. Safenowitz by the Safenowitz family – through The ALS Association Greater New York Chapter. The program encourages young scientists to enter and, importantly, to remain in the ALS field.

We are proud that 76 percent of the postdoctoral fellows we fund go on to start their own labs to continue studying ALS and mentor other young ALS researchers. The rest of our Safenowitz fellowship program graduates go on to careers in the biomedical industry, nonprofits, and medical writing, with many still staying in the ALS space.

This year, we are supporting five new postdoctoral fellows out of a highly competitive applicant pool. Over the next few weeks, we will highlight each fellow – their dedication and unique contributions to ALS research, as well as their interests outside of the lab.

We recently talked with Dr. Alyssa Coyne from Johns Hopkins University to learn about her unique research project focused on understanding the molecular mechanisms underlying the most common form of familial ALS.

Continue reading Meet Alyssa Coyne: A 2018 Milton Safenowitz Postdoctoral Fellow

Meet Edward Barbieri: A 2018 Milton Safenowitz Postdoctoral Fellow

Our Milton Safenowitz Postdoctoral Fellowship Program continues to support young scientists and is the only program of its kind specifically funding early ALS postdoctoral fellows.

The awards were founded in memory of Mr. Safenowitz by the Safenowitz family – through The ALS Association Greater New York Chapter. The program encourages young scientists to enter and, importantly, to remain in the ALS field.

We are proud that 76 percent of the postdoctoral fellows we fund go on to start their own labs to continue studying ALS and mentor other young ALS researchers. The rest of our Safenowitz fellowship program graduates go on to careers in the biomedical industry, nonprofits, and medical writing, with many still staying in the ALS space.

This year, we are supporting five new postdoctoral fellows out of a highly competitive applicant pool. Over the next few weeks, we will highlight each fellow – their dedication and unique contributions to ALS research, as well as their interests outside of the lab.

We recently talked with Dr. Edward Barbieri from the University of Pennsylvania to learn about his unique research project aimed at identify particular networks of chaperones that can reverse the toxic effects of ALS-associated proteins in cells.

Continue reading Meet Edward Barbieri: A 2018 Milton Safenowitz Postdoctoral Fellow

Looking Ahead: The Carmen Schentrup ALS Research Fund Inspires Hope and Progress Toward a Cure

Carmen Schentrup had a dream: a world without ALS. Her career aspiration was to become a medical researcher and to be part of The ALS Association’s work to cure ALS.

Tragically, Carmen’s life was cut short in the horrific Parkland shooting last year. However, her dream to contribute to a cure is being realized in a significant way.

Carmen’s birthday is today, February 21. She would have been 18 years old.

Continue reading Looking Ahead: The Carmen Schentrup ALS Research Fund Inspires Hope and Progress Toward a Cure